Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03485209 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
A Phase 2 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 352
- Enrollment target
- 20
- Study locations
NCT03485209: Active Phase 2 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT03485209 is a Phase 2 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 352 participants, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03485209, a Phase 2 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 352 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, participants will receive tisotumab vedotin every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. * Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin. The objectives of the study have been achieved. Therefore, the study will transition to a long-term extension phase (LTEP). * In LTEP, participants still receiving clinical benefit based on the investigator's assessment and remaining on treatment may continue receiving treatment. * Participants will still receive tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin
Primary Outcome
Proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG cisplatin
- DRUG carboplatin
- DRUG tisotumab vedotin
Study Locations (20)
California
- UCSD Medical Center - Encinitas - Encinitas
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) - La Jolla
- UC San Diego Moores Cancer Center - La Jolla
- UCSD Koman Family Outpatient Pavilion - La Jolla
- UC San Diego/Moores Cancer Center - La Jolla
- UCSD Shiley Eye Institute - La Jolla
- University of California Davis Medical Center - Sacramento
- University of California, Davis Comprehensive Cancer Center - Sacramento
- UC San Diego Medical Center- Hillcrest - San Diego
- UC San Diego Health - Rancho Bernardo - San Diego
- Stanford Cancer Center South Bay - San Jose
- UCSD Medical Center - Vista - Vista
Colorado
- Poudre Valley Hospital - Fort Collins
- Eye Center of Northern Colorado - Fort Collins
- Cancer Care & Hematology - Fort Collins - Fort Collins
- Eye Center of Northern Colorado - Fort Collins
- Cancer Care & Hematology - Greeley - Greeley
- Cancer Care & Hematology - Loveland - Loveland
Connecticut
- Simlow Cancer Hospitalat Yale-New Haven - New Haven
- Yale-New Haven Hospital- Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What the registry record for NCT03485209 still lists
NCT03485209 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (10% higher).
The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which pembrolizumab is the first listed.
NCT03485209 names 20 study sites across 3 states, led by California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03485209 about?
NCT03485209 is a clinical study titled "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors". This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, participants will receive tisotumab vedotin ev...
What is the current status of trial NCT03485209?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 352 participants. The study started on 2018-06-25. Estimated completion is 2027-03-31.
What conditions does trial NCT03485209 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Exocrine Pancreatic Cancer.
What interventions are being tested in trial NCT03485209?
The interventions under investigation include: pembrolizumab (DRUG), cisplatin (DRUG), carboplatin (DRUG), tisotumab vedotin (DRUG).
Who is sponsoring clinical trial NCT03485209?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03485209 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03485209's enrollment target sits among peer trials
352 36th of 130 higher than 95 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI